We’re thrilled to share that David Burdis and Brad Walsh, representing Glytherix, are heading to Hong Kong on November 23rd and 24th to explore investment opportunities for our Series A round.

    Glytherix is at the forefront of ground-breaking innovations, and we’re on the lookout for strategic partners and investors who are as passionate about biotechnology as we are.

    Looking forward to engaging with the vibrant business community in Hong Kong and exploring the potential for transformative partnerships!

    For more information please contact:
    Dr Brad Walsh, CEO Brad.Walsh@glytherix.com
    David Burdis, CFO David.Burdis@glytherix.com